DrugPatentWatch Database Preview
Drugs in Development Information for Pictilisib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Pictilisib?
Pictilisib is an investigational drug.
There have been 4 clinical trials for Pictilisib.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Gliosarcoma, and Glioblastoma. The leading clinical trial sponsors are Genentech, Inc., Department of Experimental Clinical Oncology, Aarhus University Hospital, and Royal Marsden NHS Foundation Trust.
There are one hundred and five US patents protecting this investigational drug and nine hundred and seventy-one international patents.
Summary for Pictilisib
| US Patents | 105 |
| International Patents | 971 |
| US Patent Applications | 243 |
| WIPO Patent Applications | 128 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2013-03-01) |
| Vendors | 81 |
Recent Clinical Trials for Pictilisib
| Title | Sponsor | Phase |
|---|---|---|
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Institute of Cancer Research, United Kingdom | Phase 1 |
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Pfizer | Phase 1 |
| PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Roche Pharma AG | Phase 1 |
Clinical Trial Summary for Pictilisib
Top disease conditions for Pictilisib
Top clinical trial sponsors for Pictilisib
US Patents for Pictilisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pictilisib | Start Trial | In vitro production of foregut stem cells | Cambridge Enterprise Limited (GB) | Start Trial |
| Pictilisib | Start Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | Start Trial |
| Pictilisib | Start Trial | Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Pictilisib | Start Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | Start Trial |
| Pictilisib | Start Trial | Antibody drug conjugates | Novartis AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pictilisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pictilisib | Australia | 2014333942 | 2033-10-09 | Start Trial |
| Pictilisib | Canada | 2963886 | 2033-10-09 | Start Trial |
| Pictilisib | China | 105793414 | 2033-10-09 | Start Trial |
| Pictilisib | European Patent Office | 3060652 | 2033-10-09 | Start Trial |
| Pictilisib | United Kingdom | 201317869 | 2033-10-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
